Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Pick Your #1 breakfast food - 2This St Nick Truly Can Advise How To Drink And Hack Your Headache
- 3New method spots signs of Earth's primordial life in ancient rocks
- 4German Cabinet advances bill to cut greenhouse emissions from fuels
- 5I binged all 24 Hallmark Christmas movies in less than 30 days. I emerged a changed man.
- Flu cases are spiking earlier than usual. What you need to know.
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- How to watch 'A Charlie Brown Christmas' for free this weekend
- How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
- 23 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- Banks for High Fixed Store Rates: Amplify Your Reserve funds
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- NASA's Voyager 1 set to achieve historic distance from Earth
